PredictImmune sets up IBD CAB to boost access to PredictSURE IBD™ test
Category: #health  By Pankaj Singh  Date: 2021-02-03
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

PredictImmune sets up IBD CAB to boost access to PredictSURE IBD™ test

PredictImmune, a global biotechnology company, has reportedly confirmed the convening of its IBD CAB (Clinical Advisory Board). The IBD CAB has been set up with an aim to provide a platform for healthcare professionals to share their expertise and experiences in prognostic risk stratification & treatment guidance.

PredictSURE IBD™ has been developed as a blood-based biomarker test to stratify prognostic risks of disease severity. This provides information to the gastroenterologist to ensure the appropriate selection of treatment options. The test was formed based on the 15-year clinical research on the gene expression profiling of CD8+ T cells in connection with the long-term outcomes of the patients with Crohn’s disease and ulcerative colitis.

According to Prof. Dr. Severine Vermeire, PredictImmune IBD Clinical Advisory Board’s Chairperson, the PredictSURE IBD™ prognostic test is expected to become the 1st biomarker test that will assist physicians in predicting future diseases among patients with inflammatory bowel disease, based on which, relevant therapeutic choices and intensity of follow up will be directed. The effectiveness of this test is presently being examined in the PROFILE clinical trial in the UK.

Six leading IBD KOLs joined Dr. Severine Vermeire to the Board to identify region-specific requirements and opportunities for the adoption of the PredictSURE IBD™ test.

Andrew Sandham, PredictImmune’s Chairman, has reportedly cited that the company is excited to add highly experienced & prolific clinical professional advisors to its IBD Clinical Advisory Board. It has closely partnered with these clinicians during the development of the PredictSURE IBD™ prognostic test, which is expected to result in the significant expansion of the scope of the advisors across major countries in Europe. This will also allow them to ensure optimal access to PredictSURE IBD™ in each country. Additionally, the guidance of IBD CAB will boost the effectiveness of its mission to surge the availability of the test for patients and clinicians in Europe.

Source credit:
https://www.businesswire.com/news/home/20210201005769/en/PredictImmune-establishes-IBD-Clinical-Advisory-Board-to-advise-on-European-access-to-PredictSURE-IBD%E2%84%A2



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

By Pankaj Singh

Bioheng Biotech Co. Ltd. has reportedly announced that its CD7-targeting T-cell therapy product, code CTD401, has obtained the Orphan Drug Designation (ODD) from the US FDA for treating T-cell acute lymphoblastic leuke...

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

By Pankaj Singh

Biotechnology company, Tiziana Life Sciences plc, has reportedly announced the submission of a grant to the UK-CTAP (United Kingdom COVID Therapeutics Advisory Panel).

This ...